Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Emeritus Professor Herbie Newell

Newcastle AuthorsTitleYearFull text
Christopher Matheson
Christopher Coxon
Dr Benoit Carbain
Dr Ian Hardcastle
Dr Suzannah Harnor
et al.
2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase2020
Emeritus Professor Herbie Newell
A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA2019
Stephanie Myers
Duncan Miller
Dr Lauren Molyneux
Dr Mercedeh Arasta
Dr Ruth Bawn
et al.
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD42019
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Calum Kirk
Dr Katrina Wood
et al.
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma2019
Dr Catherine Willoughby
Huw Thomas
Dr Elaine Willmore
Suzanne Kyle
Dr Anita Wittner
et al.
Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy2019
Honorine Lebraud
Dr Richard Noble
Nicole Phillips
Dr Yan Zhao
Emeritus Professor Herbie Newell
et al.
A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition2018
Christopher Coxon
Dr Suzannah Harnor
Dr Mathew Martin
Dr Benoit Carbain
Professor Bernard Golding
et al.
Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines2017
Emeritus Professor Herbie Newell
Discovery & pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor2017
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Dr Katrina Wood
Professor Gareth Veal
et al.
In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma2017
Carlo Bawn
Martin Galler
Huw Thomas
Suzanne Kyle
Professor Nicola Curtin
et al.
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS2017
12